Nintedanib ameliorates animal model of dermatitis

Nintedanib, a receptor tyrosine kinase (RTK) inhibitor has been developed as therapeutics for idiopathic pulmonary fibrosis and non-small lung cancer. We found that the expression levels of RTK, especially VEGFR1 is increased in skin biopsies of dermatitis patients from multiple independent datasets...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Min-Jeong, Lee, Chanmi, Choi, Soo Young, Choi, Yeong Min, An, In-sook, Bae, Seunghee, An, Sungkwan, Jung, Jin Hyuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066145/
https://www.ncbi.nlm.nih.gov/pubmed/32161331
http://dx.doi.org/10.1038/s41598-020-61424-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066145/
https://www.ncbi.nlm.nih.gov/pubmed/32161331
http://dx.doi.org/10.1038/s41598-020-61424-1

Ejemplares similares